The Efficacy And Safety Of Ruxolitinib With Myelofibrosis

Objective:The efficacy and safety of ruxolitinib with myelofibrosis.Methods:This study enrolled 20 myelofibrosis patients(11 males and 9 females)in total,whose median age was 57(49-75),including 17 patients with PMF,2 patients with Post-PV MF and 1 patients with Post-ET MF.All of them met the diagnostic criteria of 2016 WHO.10 cases received ruxolitinib therapy and 10 cases received the best available therapy.The primary endpoint was to follow up the proportion of patients with at least a 50% reduction in total symptom scores assessed by MPN-SAF-TSS(MPN Symptom Assessment Form-Total Symptom Score)in half a year,observe the decrease in spleen size of patients,and the adverse events.Results:8 patients(80%)had at least a 50% reduction in the Total Symptom Score in ruxolitinib group,the quality of life are better than before.2 patients(20%)had at least a 50% reduction in Total Symptom Score in the best available therapy,(P=0.023).The rate of improvement of physical symptoms in ruxolitinib group was24.344 times higher than that in the best available therapy(P=0.025,OR=24.344).After following up for half a year,the length of spleen was 7.9±5.15 cm shorter than before(P=0.001).In ruxolitinib group,the main adverse events were hematologyical adverse events,anemia occurred in 7 patients(70%),of which 3(30%)were grade3 anemia,and grade1 thrombocytopenia in 2 patients(20%),grade4 thrombocytopenia in 1 patients(10%).The main non-hematologic adverse events were transominase elevation,abdominal distension and insomnia occurred in 2patients each(20%),most of them were grade1/2 adverse event.Grade3 anemia occurred in 3 patients(30%)with the best available therapy,other more common adverse events were thrombocytopenia and leukopenia,occurred in 2 patients each(20%),each case has a grade3 adverse event.Grade3/4 neutropenia occurred in 1 patient,fatigue,headache,constipation,abdominal distension and diarrhea occurred in 1 patient each(10%),all of them were grade1/2 adverse events.Conclusion:Ruxolitinib reduced the spleen size of patients with myelofibrosis,improved physical symptoms and quality of life,the adverse events were tolerated.